US FDA approves KalVista Pharma's swelling disorder drug-March 2024-www.financetom.com

US FDA approves KalVista Pharma's swelling disorder drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025 3:55 AM

July 7 (Reuters) - The U.S. Food and Drug Administration

approved KalVista Pharmaceuticals' ( KALV ) drug for a type of

hereditary swelling disorder, the company said on Monday.

(Reporting by Puyaan Singh in Bengaluru; Editing by Arun

Koyyur)

Previous page： Consulting firm Huron's Q3 revenue up on increased demand Next page： Atlassian Insider Sold Shares Worth $1,264,963, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Consulting firm Huron's Q3 revenue up on increased demand

Oct 28, 2025

Overview * Huron Q3 2025 rev rises 16.8% yr/yr, beating analyst expectations * Adjusted diluted EPS for Q3 2025 increases 25% Outlook * Huron raises 2025 adjusted diluted EPS guidance midpoint to $7.60 * Company narrows 2025 revenue guidance to $1.65 bln-$1.67 bln * Huron expects 2025 adjusted EBITDA margin between 14.0% and 14.5% Result Drivers * SEGMENT GROWTH -...

Atlassian Insider Sold Shares Worth $1,264,963, According to a Recent SEC Filing

Oct 28, 2025

04:36 PM EDT, 10/28/2025 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, CEO, Co-Founder, on October 27, 2025, sold 7,665 shares in Atlassian ( TEAM ) for $1,264,963. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 344,925 Class A common shares of the company, with 344,925 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000166612025000053/xslF345X05/primarydocument.xml ...

Celanese Announces Agreement to Divest Micromax® Business

Oct 28, 2025

Purchase price of approximately $500 million, subject to adjustment, net proceeds of which will be dedicated to deleveraging Current pro forma run rate EBITDA of the business in 2025 is approximately $40 million DALLAS--(BUSINESS WIRE)-- Celanese Corporation ( CE ) , a global specialty materials and chemical company, announced today it has signed a definitive agreement to divest the Micromax®...

Logitech International Fiscal Q2 Non-GAAP Earnings, Net Sales Rise; Shares Up After Hours

Oct 28, 2025

04:36 PM EDT, 10/28/2025 (MT Newswires) -- Logitech International ( LOGI ) reported fiscal Q2 non-GAAP earnings late Tuesday of $1.45 per diluted share, up from $1.20 a year earlier. Analysts polled by FactSet expected $0.96. Net sales for the quarter ended Sept. 30 were $1.18 billion, compared with $1.16 billion a year earlier. Analysts surveyed by FactSet expected $941...